When there is a pandemic there is no time to waste: should we have hydroxychloroquine in our armoury against COVID-19 infected patients?
Identifieur interne : 001688 ( Main/Corpus ); précédent : 001687; suivant : 001689When there is a pandemic there is no time to waste: should we have hydroxychloroquine in our armoury against COVID-19 infected patients?
Auteurs : Dimitrios P. Bogdanos ; Zoi Daniil ; Epaminondas Zakynthinos ; Konstantinos Gourgoulianis ; Lazaros I. SakkasSource :
- Mediterranean journal of rheumatology [ 2529-198X ] ; 2020.
Abstract
The current use of chloroquine and/or hydroxychloroquine, a drug currently used to treat autoimmune rheumatic diseases, in treating severe acute respiratory syndrome caused by coronavirus 2 (SARSCoV-2) or COVID-19-infected patients with pneumonia is a matter of intense consideration. We wish to enter the ongoing debate as to whether this well-known drug must be given to Greek COVID-19-infected patients, especially those with pneumonia. Our arguments are based on the existing data and the capacity of the Greek health system to afford potent anti-viral treatments, which are under immense investigation. We propose several suggestions related to treatment of COVID-19 pneumonia with chloroquine/hydroxychloroquine that we think must be taken into consideration to fit the evolving situation of the pandemic in Greece.
DOI: 10.31138/mjr.31.1.94
PubMed: 32411941
PubMed Central: PMC7219635
Links to Exploration step
pubmed:32411941Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">When there is a pandemic there is no time to waste: should we have hydroxychloroquine in our armoury against COVID-19 infected patients?</title><author><name sortKey="Bogdanos, Dimitrios P" sort="Bogdanos, Dimitrios P" uniqKey="Bogdanos D" first="Dimitrios P" last="Bogdanos">Dimitrios P. Bogdanos</name><affiliation><nlm:affiliation>Department of Rheumatology and Clinical Immunology.</nlm:affiliation></affiliation></author><author><name sortKey="Daniil, Zoi" sort="Daniil, Zoi" uniqKey="Daniil Z" first="Zoi" last="Daniil">Zoi Daniil</name><affiliation><nlm:affiliation>Department of Respiratory Medicine, and.</nlm:affiliation></affiliation></author><author><name sortKey="Zakynthinos, Epaminondas" sort="Zakynthinos, Epaminondas" uniqKey="Zakynthinos E" first="Epaminondas" last="Zakynthinos">Epaminondas Zakynthinos</name><affiliation><nlm:affiliation>Intensive Care Unit, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.</nlm:affiliation></affiliation></author><author><name sortKey="Gourgoulianis, Konstantinos" sort="Gourgoulianis, Konstantinos" uniqKey="Gourgoulianis K" first="Konstantinos" last="Gourgoulianis">Konstantinos Gourgoulianis</name><affiliation><nlm:affiliation>Department of Respiratory Medicine, and.</nlm:affiliation></affiliation></author><author><name sortKey="Sakkas, Lazaros I" sort="Sakkas, Lazaros I" uniqKey="Sakkas L" first="Lazaros I" last="Sakkas">Lazaros I. Sakkas</name><affiliation><nlm:affiliation>Department of Rheumatology and Clinical Immunology.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32411941</idno><idno type="pmid">32411941</idno><idno type="doi">10.31138/mjr.31.1.94</idno><idno type="pmc">PMC7219635</idno><idno type="wicri:Area/Main/Corpus">001688</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001688</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">When there is a pandemic there is no time to waste: should we have hydroxychloroquine in our armoury against COVID-19 infected patients?</title><author><name sortKey="Bogdanos, Dimitrios P" sort="Bogdanos, Dimitrios P" uniqKey="Bogdanos D" first="Dimitrios P" last="Bogdanos">Dimitrios P. Bogdanos</name><affiliation><nlm:affiliation>Department of Rheumatology and Clinical Immunology.</nlm:affiliation></affiliation></author><author><name sortKey="Daniil, Zoi" sort="Daniil, Zoi" uniqKey="Daniil Z" first="Zoi" last="Daniil">Zoi Daniil</name><affiliation><nlm:affiliation>Department of Respiratory Medicine, and.</nlm:affiliation></affiliation></author><author><name sortKey="Zakynthinos, Epaminondas" sort="Zakynthinos, Epaminondas" uniqKey="Zakynthinos E" first="Epaminondas" last="Zakynthinos">Epaminondas Zakynthinos</name><affiliation><nlm:affiliation>Intensive Care Unit, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.</nlm:affiliation></affiliation></author><author><name sortKey="Gourgoulianis, Konstantinos" sort="Gourgoulianis, Konstantinos" uniqKey="Gourgoulianis K" first="Konstantinos" last="Gourgoulianis">Konstantinos Gourgoulianis</name><affiliation><nlm:affiliation>Department of Respiratory Medicine, and.</nlm:affiliation></affiliation></author><author><name sortKey="Sakkas, Lazaros I" sort="Sakkas, Lazaros I" uniqKey="Sakkas L" first="Lazaros I" last="Sakkas">Lazaros I. Sakkas</name><affiliation><nlm:affiliation>Department of Rheumatology and Clinical Immunology.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Mediterranean journal of rheumatology</title><idno type="eISSN">2529-198X</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The current use of chloroquine and/or hydroxychloroquine, a drug currently used to treat autoimmune rheumatic diseases, in treating severe acute respiratory syndrome caused by coronavirus 2 (SARSCoV-2) or COVID-19-infected patients with pneumonia is a matter of intense consideration. We wish to enter the ongoing debate as to whether this well-known drug must be given to Greek COVID-19-infected patients, especially those with pneumonia. Our arguments are based on the existing data and the capacity of the Greek health system to afford potent anti-viral treatments, which are under immense investigation. We propose several suggestions related to treatment of COVID-19 pneumonia with chloroquine/hydroxychloroquine that we think must be taken into consideration to fit the evolving situation of the pandemic in Greece.</div></front></TEI><pubmed><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">32411941</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2529-198X</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Mediterranean journal of rheumatology</Title><ISOAbbreviation>Mediterr J Rheumatol</ISOAbbreviation></Journal><ArticleTitle>When there is a pandemic there is no time to waste: should we have hydroxychloroquine in our armoury against COVID-19 infected patients?</ArticleTitle><Pagination><MedlinePgn>94-97</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.31138/mjr.31.1.94</ELocationID><Abstract><AbstractText>The current use of chloroquine and/or hydroxychloroquine, a drug currently used to treat autoimmune rheumatic diseases, in treating severe acute respiratory syndrome caused by coronavirus 2 (SARSCoV-2) or COVID-19-infected patients with pneumonia is a matter of intense consideration. We wish to enter the ongoing debate as to whether this well-known drug must be given to Greek COVID-19-infected patients, especially those with pneumonia. Our arguments are based on the existing data and the capacity of the Greek health system to afford potent anti-viral treatments, which are under immense investigation. We propose several suggestions related to treatment of COVID-19 pneumonia with chloroquine/hydroxychloroquine that we think must be taken into consideration to fit the evolving situation of the pandemic in Greece.</AbstractText><CopyrightInformation>© 2020 The Mediterranean Journal of Rheumatology (MJR).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bogdanos</LastName><ForeName>Dimitrios P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Daniil</LastName><ForeName>Zoi</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zakynthinos</LastName><ForeName>Epaminondas</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Intensive Care Unit, Faculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gourgoulianis</LastName><ForeName>Konstantinos</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Respiratory Medicine, and.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakkas</LastName><ForeName>Lazaros I</ForeName><Initials>LI</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Clinical Immunology.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>03</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Greece</Country><MedlineTA>Mediterr J Rheumatol</MedlineTA><NlmUniqueID>101730166</NlmUniqueID><ISSNLinking>2529-198X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID19</Keyword><Keyword MajorTopicYN="N">chloroquine</Keyword><Keyword MajorTopicYN="N">hydroxychloroquine</Keyword><Keyword MajorTopicYN="N">pandemic</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>03</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>03</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>5</Month><Day>16</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32411941</ArticleId><ArticleId IdType="doi">10.31138/mjr.31.1.94</ArticleId><ArticleId IdType="pii">MJR-31-1-94</ArticleId><ArticleId IdType="pmc">PMC7219635</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhonghua Jie He He Hu Xi Za Zhi. 2020 Mar 12;43(3):185-188</Citation><ArticleIdList><ArticleId IdType="pubmed">32164085</ArticleId></ArticleIdList></Reference><Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation><ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Antimicrob Agents. 2020 Mar 12;:105938</Citation><ArticleIdList><ArticleId IdType="pubmed">32171740</ArticleId></ArticleIdList></Reference><Reference><Citation>Antiviral Res. 2008 Feb;77(2):150-2</Citation><ArticleIdList><ArticleId IdType="pubmed">18055026</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Infect Dis. 2020 Mar 09;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32150618</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2009 Aug;53(8):3416-21</Citation><ArticleIdList><ArticleId IdType="pubmed">19506054</ArticleId></ArticleIdList></Reference><Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation><ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Biophys Res Commun. 2004 Oct 8;323(1):264-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15351731</ArticleId></ArticleIdList></Reference><Reference><Citation>J Crit Care. 2020 Mar 10;:</Citation><ArticleIdList><ArticleId IdType="pubmed">32173110</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet Infect Dis. 2006 Feb;6(2):67-9</Citation><ArticleIdList><ArticleId IdType="pubmed">16439323</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Res Perspect. 2017 Jan 23;5(1):e00293</Citation><ArticleIdList><ArticleId IdType="pubmed">28596841</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001688 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001688 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32411941
|texte= When there is a pandemic there is no time to waste: should we have hydroxychloroquine in our armoury against COVID-19 infected patients?
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32411941" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |